Breast Cancer Research – Dr. Gorski
My research focuses primarily on two areas. First, I have had a long-standing interest in tumor-induced angiogenesis and how best to target it therapeutically. Potential targets that we have studied include homeobox genes, master regulatory genes that can control vascular endothelial cell phenotype, and glutamatergic signaling. My second area of interest, which aligns with my clinical interest, is glutamatergic signaling as a potential therapeutic target in Triple Negative Breast Cancer (TNBC), a highly aggressive form of breast cancer that expresses neither estrogen receptor, progesterone receptor, nor amplified HER2. TNBC proportionally results in more breast cancer deaths because it metastasizes earlier and tends to recur after surgery. Unfortunately, the only current systemic therapy for TNBC is cytotoxic chemotherapy. We have found that glutamatergic signaling appears to be important in regulating TNBC growth and that targeting it in preclinical models has been successful in inhibiting the growth of TNBC xenografts. Finally, we have recently begun a collaboration with Manohar Ratnam, PhD in the Department of Oncology and investigators at Henry Ford Hospital to study the use of folate receptor-targeted imaging and treatment in TNBC.